Dental Equipment and Supplies Manufacturing (U.S.) — NAICS 339114

1. Overview

This industry makes the tools and materials dentists use — dental chairs and drills, X-ray and 3D imaging units, hand instruments, implants, orthodontic braces and clear aligners, impression materials, cements, and the digital scanners and mills that now sit in modern practices. It does not include the dentists themselves, the labs that make custom crowns for individual patients, or the wholesalers that distribute the products (all covered below).

Why an investor should care: dental care is a large, recurring, partly recession-resistant category, but the high-value products here — implants, aligners, cosmetic and digital equipment — are elective and largely paid out of pocket, which makes the industry a hybrid of steady consumables demand and discretionary, cyclical big-ticket sales. It is also mid-cycle in a decades-long shift from analog to digital dentistry, which drives an equipment-replacement wave.

Ways in: Public-market investors have a handful of mid-to-large-cap pure(ish) plays — Align Technology, Dentsply Sirona, and Envista — plus diversified exposure through Solventum (dental is one segment) and Swiss-listed Straumann. Private investors reach the industry mainly through private equity: many important manufacturers are privately held (Ivoclar, Ultradent, Planmeca, A-dec) or PE-owned (ZimVie), and PE is deeply invested in the customer base (dental practice roll-ups) and distribution.

2. What it is and how it's structured

Scope. NAICS (North American Industry Classification System) code 339114 covers establishments that manufacture dental equipment and supplies used by dentists and dental labs — dental chairs and delivery systems, hand instruments, drills and handpieces, X-ray and imaging machines, sterilizers and lab furnaces, impression materials, cements and waxes, implants, and orthodontic appliances including clear aligners.[1][2][3]

What it excludes (name the adjacent codes, because household "dental" names sit in them):

• NAICS 339116 — Dental Laboratories: the labs that fabricate crowns, bridges, dentures, and orthodontic appliances customized for one patient. Making the blank materials is 339114; making a specific patient's crown is 339116.[2][3]
• NAICS 423450 — Medical, Dental & Hospital Equipment & Supplies Merchant Wholesalers: the distributors that sell to practices — Henry Schein and Patterson Companies. They are the channel, not manufacturers.
• NAICS 621210 — Offices of Dentists: the customers.
• NAICS 339112 — Surgical and Medical Instrument Manufacturing: general (non-dental) medical devices.
• Consumer oral care (toothpaste, mouthwash) sits in toilet-preparation manufacturing, not here.

Commercial structure. The industry divides into several businesses with different economics:

• Consumables — restorative materials, bonding agents, cements, impression materials, burs, endodontic files, and infection-control products. These are recurring, procedure-linked purchases.
• Equipment — treatment centers, chairs, delivery units, handpieces, sterilizers, imaging systems, intraoral scanners, and CAD/CAM systems. Larger tickets, longer replacement cycles, and greater sensitivity to dentist confidence and credit availability.
• Specialty products — implants, orthodontic brackets, and clear aligners. These generally require clinical education, treatment-planning support, and substantial intellectual property.
• Digital workflows — linking imaging, scanning, treatment planning, chairside or laboratory fabrication, software, and consumables. Vendors increasingly compete for control of that workflow rather than for an isolated instrument.

Distribution. Manufacturers typically sell through specialized distributors, although implants, orthodontics, and some digitally enabled products are often sold directly. Dentsply Sirona reports that approximately two-thirds of its dental consumable, technology, and equipment products are sold through third-party distributors; Henry Schein alone represented 13% of its 2025 sales.[4] Envista's Equipment & Consumables segment generated approximately 89% of its 2025 sales through channel partners.[5] Distribution provides reach and service capacity but introduces customer concentration, inventory-cycle noise, and bargaining pressure.

Ownership mix. A few large, multinational, mostly public companies generate the bulk of revenue, sitting atop a long tail of small private manufacturers. Federal data counts 464 firms across 503 U.S. establishments[1][2] — most are small (the U.S. Small Business Administration size standard for this industry is 750 employees[6]) — but the top handful capture most of the sales.

3. How big it is

From our ground-truth federal statistics (U.S. Census Bureau):

The undercount caveat matters a lot here. The ~$5.8 billion figure measures what is physically manufactured in U.S. establishments classified in 339114. It substantially understates what U.S. dentists actually spend, for two reasons. First, a large share of dental product — implants, aligner inputs, low-cost instruments — is imported or made offshore, including by the same U.S.-headquartered companies (much clear-aligner production, for example, happens outside the U.S.).[7] Second, the leaders are global: Align Technology reported ~$4.0 billion in worldwide revenue in 2025, Dentsply Sirona ~$3.68 billion, and Envista ~$2.72 billion[8][9][10] — figures that dwarf the domestic-production total because they include overseas manufacturing and sales. Read the $5.8 billion as U.S. factory output, not the size of the U.S. dental-products market, which private research firms put higher and growing (one estimate of the U.S. dental-equipment segment alone is ~$5.9 billion in 2025 rising to ~$7.6 billion by 2030).[11]

For context, U.S. dental-services spending — the revenue pool of dental-care providers from which equipment and consumable purchases are funded — reached $189.2 billion in 2024, up 6.6% from 2023. Private insurance and out-of-pocket payments together accounted for 80% of that spending.[12]

4. The investable universe

There is no single, giant, pure-play "U.S. dental supplies manufacturer." The listed universe is a short list of mid-to-large caps, and the private/PE side is arguably larger and more fragmented.

Public companies (market values approximate, mid-2026):

Distributors (adjacent, not manufacturers) give indirect exposure: Henry Schein (HSIC) remains the leading listed distributor. Patterson Companies was taken private by Patient Square Capital in April 2025 in a ~$4.1 billion deal.[16][17]

Major private / PE-owned / other owners:

• ZimVie — dental-implant maker, formerly public (ZIMV); taken private by French healthcare PE firm ArchiMed for ~$730 million (closing around end-2025).[18]
• A-dec — privately held, Oregon-based; one of the largest privately owned U.S. dental-equipment manufacturers (treatment centers, chairs, delivery systems).[19]
• Ivoclar (Ivoclar Vivadent) — Liechtenstein; private; aesthetic materials.
• Ultradent Products — private, Utah; Opalescence whitening and materials.
• Planmeca (Finland) — private; imaging, treatment units, CAD/CAM, and software.[20]
• GC Corporation (Japan) — private; global manufacturer of dental materials, devices, and equipment.[21]
• Aligner challengers: Angel Aligner (China), plus Envista's Spark and Straumann's ClearCorrect; SmileDirectClub, the direct-to-consumer pioneer, went bankrupt in 2023.

5. How the money works

Owners make money two very different ways, and the mix defines the business:

• Capital equipment (chairs, imaging units, CAD/CAM — computer-aided design/computer-aided manufacturing — mills, intraoral scanners). Big-ticket (premium scanners list at $20,000–$50,000), lumpy, and cyclical — sales rise and fall with dentists' willingness to spend on their practices.[22]
• Consumables and recurring products (impression materials, cements, implants, aligner cases, whitening, software subscriptions). Recurring, higher-margin, and sticky. Consumables are roughly 40%+ of the broader market precisely because they are used at every visit; at Envista, consumables, service, and spare parts constitute approximately 70% of the Equipment & Consumables segment.[10][22]

The winning model is "razor-and-blade": place a scanner or mill, then earn a recurring stream from proprietary materials, per-case fees, and software. Proprietary consumables plus locked-in software create an installed-base moat. Gross margins are high — clear aligners and implants can run near 70% gross — but so are the costs of selling to dentists (large sales forces, clinical education) and, for aligners, marketing directly to consumers.

Major cost drivers include metals and machined components, electronic components and sensors, resins and other chemicals, plastics, packaging, direct labor, regulatory quality systems, freight, warranty, and field service. Some qualified components have only one or a few suppliers, and switching suppliers can require regulatory validation.[10]

The metrics owners and investors actually watch:

• Organic (core) sales growth — volume/price growth stripping out currency and acquisitions.
• Aligner case/shipment volumes and average selling price (ASP) — the swing factor for Align.
• Implant unit volumes and scanner/equipment unit sales and the size of the installed base.
• Gross margin and R&D as a percent of sales (this is an innovation race).
• Cyclicality and the cash-pay mix: because implants, aligners, whitening, and cosmetic work are largely out of pocket (implants run ~$2,000–$4,500 per tooth; aligners ~$1,000–$7,000)[23][24], demand tracks consumer confidence, and equipment demand tracks practice profitability.

6. What drives demand

• Underlying disease burden. CDC reports that nearly 21% of adults aged 20–64 had untreated decay and that adults in that group with dental disease averaged 6.0 filled and 2.0 disease-related missing teeth.[25] Disease prevalence, however, is not automatically commercial demand: coverage, income, dentist availability, and willingness to seek care determine conversion.
• Aging population. Americans 65+ are projected to grow from about 58 million (2022) to 82 million by 2050[26] — the prime demographic for implants and restorative work; implant use has risen fastest among older adults.
• Aesthetics and adult orthodontics. Adults now make up the majority (~65%) of the clear-aligner market — cosmetic, elective, and cash-pay.[24]
• Digital transformation. The shift to intraoral scanners, same-day CAD/CAM, in-office 3D printing, and AI (artificial-intelligence) imaging is driving an equipment upgrade cycle; digital dental equipment is growing double digits. Digital systems create recurring service, software, and consumables opportunities, but faster technology cycles increase R&D and inventory-obsolescence risk.[22]
• DSO consolidation. Dental Service Organizations (DSOs) — management companies that own or support many practices, often private-equity-backed — standardize purchasing and adopt digital workflows faster. ADA data show that 27% of dentists fewer than ten years out of dental school were DSO-affiliated in 2024, compared with 9% of dentists more than 25 years out.[27] Align has publicly targeted DSOs as ~50% of its customer base by 2035.[28] DSOs can accelerate a successful product rollout, but they negotiate harder and can shift share quickly.
• Practice economics and reimbursement. Most routine dentistry runs through private dental insurance; Medicare covers little (some expansion for medically necessary care). The high out-of-pocket share means affordability and consumer confidence gate demand for the profitable procedures.
• Access and staffing constraints. As of March 2026, HRSA counted 70.6 million people in designated dental shortage areas.[29] ADA reported in April 2026 that only 60% of dentists considered their hygienist staffing adequate and that 91% of dentists recruiting hygienists found the process extremely challenging.[30] Labor-saving technology can benefit, but fewer staffed chairs cap near-term procedure and consumable volumes.

7. Regulation

Dental products are medical devices regulated by the U.S. Food and Drug Administration (FDA) under 21 CFR Part 872.[31] Risk-based classes drive the compliance burden:

• Class I (low risk — most hand instruments): often exempt from premarket review, but exempt devices remain subject to applicable general controls.[32]
• Class II (moderate risk — implants, clear aligners, scanners, most equipment): typically require a 510(k) premarket notification, in which the maker shows "substantial equivalence" to an already-marketed predicate device.[31]
• Class III (high risk): rare in dentistry.

Manufacturers must register establishments with the FDA, list their devices, and follow quality-system rules; materials must meet biocompatibility standards. FDA's Quality Management System Regulation (QMSR) became effective on February 2, 2026, incorporating ISO 13485:2016 into U.S. device manufacturing requirements and expanding the records available for inspection.[33] Compliance failures can produce warning letters, recalls, import restrictions, remediation expense, or lost manufacturing time.

Other regulatory pressures: the global phase-down of dental amalgam (mercury) under the Minamata Convention; state dental-board scrutiny of direct-to-consumer aligners (a factor in SmileDirectClub's collapse); and, for exports, Europe's CE marking / EU Medical Device Regulation and the ISO 13485 quality standard. Trade policy is a live regulatory-adjacent risk: tariffs on Chinese imports (dental goods have been swept into successive rounds, with medical-device duties layered on) raise input and finished-goods costs across the supply chain.[7]

8. Competitive dynamics and consolidation

Federal data shows a moderately concentrated top with a long tail: the four largest firms hold about 45% of U.S. revenue, the top eight about 66%, and the top 50 roughly 93% — yet the Herfindahl-Hirschman Index (HHI, a standard concentration measure) is only ~665, which the U.S. antitrust agencies would call unconcentrated (below 1,500).[2] In plain terms: a few branded leaders dominate the marquee categories, but hundreds of small specialists fill niches.

Consolidation has been the defining theme:

• Manufacturer mergers: Dentsply and Sirona merged in 2016; Danaher rolled up dental brands and spun them out as Envista in 2019; Straumann has acquired aggressively.
• Private equity going deeper: ZimVie taken private by ArchiMed (~$730M)[18]; distributor Patterson taken private by Patient Square (~$4.1B, closed April 2025).[16][17]
• Aligner competition intensified after Align's foundational Invisalign patents expired around 2017, opening the field to 3M/Solventum, Straumann's ClearCorrect, Envista's Spark, and China's Angel Aligner — adding price pressure to what was once a near-monopoly.[34]
• Channel and buyer power: consolidated distributors (Schein, formerly Patterson) and consolidating DSO buyers both squeeze manufacturer pricing.

9. Risks

• Discretionary/cyclical demand. Implants, aligners, cosmetic work, and equipment capex are elective; recessions and weak consumer confidence hit them directly.
• Tariffs and supply chain. Heavy reliance on Chinese and overseas production exposes costs to shifting tariff policy. A nominally U.S. manufacturer may have a globally distributed component and manufacturing footprint.[7]
• Currency. The leaders earn most revenue abroad, so a strong dollar depresses reported results.
• Commoditization and price competition, especially in aligners post-patent-expiry.[34]
• Concentration on blockbusters — e.g., Align's dependence on Invisalign.
• Reimbursement and affordability — limited insurance coverage caps volume for the profitable procedures.
• Regulatory and litigation — FDA requirements, QMSR compliance, mercury phase-down, DTC-aligner scrutiny, and antitrust/patent disputes.
• Equipment obsolescence and inventory write-downs when scanner, imaging, or CAD/CAM platforms turn over faster than anticipated.
• Cybersecurity, privacy, and software-validation risk as imaging and treatment planning move to connected platforms.
• Practitioner and hygienist shortages, which can limit procedures despite high underlying oral-health need.[29][30]
• Channel concentration and destocking. Manufacturer shipments may fall even when end-user consumption is stable; distributor inventory cycles add noise.
• Practice-economics squeeze — rising supply costs plus flat insurance reimbursement pressure the dentists who buy the equipment.

10. How to invest and the outlook

Public routes. The cleanest exposures are Align (aligners + scanners), Envista (implants, orthodontics, diagnostics), and Dentsply Sirona (broad-line, currently in turnaround). For diversified or foreign exposure, Solventum (dental is one of four segments) and Swiss-listed Straumann (ADR: SAUHY). Distribution exposure comes via Henry Schein (Patterson is now private). Note two things: this is a small listed universe of mid/large caps, and income is scarce — Align pays no dividend and Dentsply eliminated its dividend to pay down debt[35] — so returns depend on growth and buybacks, and the stocks have been volatile.

Private routes. Much of the industry is only reachable privately: key manufacturers are family/private-owned (Ivoclar, Ultradent, Planmeca, A-dec) or PE-owned (ZimVie), and private equity is arguably more exposed to dentistry through the customers (DSO roll-ups) and distribution than through the factories. Private investors participate via buyout/PE funds, direct DSO investment, or acquiring supply, lab, or distribution businesses.

Outlook (forward-looking judgment). The structural case is genuinely strong: aging demographics, rising aesthetics demand, and the digital/DSO transition support secular growth — market researchers project high-single-digit growth for implants (~8.5% a year to the mid-2030s) and double-digit growth for clear aligners.[23][24] Against that, the near-term picture is choppy: soft consumer and elective demand, tariff and China exposure, currency headwinds, aligner price competition, and equipment-capex cyclicality. The distinction worth holding onto: the demand growth story is real and durable, but the equities have been volatile and several leaders are mid-turnaround (Dentsply) or defending margins (Envista, Align) — so timing, valuation, and management execution matter as much as the tailwind.

---

Sources

1. U.S. Census Bureau, County Business Patterns 2023, NAICS 339114 (employment, establishments, payroll). https://www.census.gov/programs-surveys/cbp.html
2. U.S. Census Bureau, 2022 Economic Census — Concentration & Selected Statistics, NAICS 339114 (receipts, firm count, CR4/CR8/CR20/CR50, HHI). https://www.census.gov/programs-surveys/economic-census.html
3. U.S. Census Bureau, 2022 NAICS Definition — 339114. https://www.census.gov/naics/?details=3391&input=339&year=2022
4. Dentsply Sirona, 2025 Form 10-K (segment revenue, distribution channels). https://www.sec.gov/Archives/edgar/data/818479/000081847926000075/xray-20251231.htm
5. Envista Holdings, 2025 Form 10-K (segment revenue, distribution channels, cost drivers). https://www.sec.gov/Archives/edgar/data/1757073/000175707326000011/nvst-20251231.htm
6. U.S. Small Business Administration, Table of Small Business Size Standards, NAICS 339114 (750 employees), 2023. https://www.sba.gov/document/support-table-size-standards
7. iData Research, "Dental US Tariffs 2025: Who's Losing, Who's Gaining?" 2025. https://idataresearch.com/dental-us-tariffs-2025-whos-losing-whos-gaining/
8. Align Technology, 2025 Form 10-K (revenue, segment breakdown, margins). https://www.sec.gov/Archives/edgar/data/1097149/000109714926000014/algn-20251231.htm
9. Dentsply Sirona, Q4 2025 Earnings Release. https://www.sec.gov/Archives/edgar/data/818479/000081847926000072/dentsplysirona8kq42025ex991.htm
10. Envista Holdings, 2025 Form 10-K (revenue, segment breakdown, consumables share). https://www.sec.gov/Archives/edgar/data/1757073/000175707326000011/nvst-20251231.htm
11. Mordor Intelligence, "USA Dental Equipment Market Size, Analysis, Growth & Forecast," 2025. https://www.mordorintelligence.com/industry-reports/usa-dental-devices-market
12. CMS, National Health Expenditures 2024 Highlights (dental services spending). https://edit.cms.gov/files/document/highlights.pdf
13. CompaniesMarketCap, "Align Technology (ALGN) — Market capitalization," 2026. https://companiesmarketcap.com/align-technology/marketcap/
14. Solventum, 2025 Form 10-K (Dental Solutions segment revenue and margin). https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/solv-20251231.htm
15. Straumann Group, 2025 Annual Report. https://www.straumann.com/group/en/discover/annualreport/2025.html
16. Patterson Companies, "Patterson Companies Completes Acquisition by Patient Square Capital," April 2025. https://www.pattersoncompanies.com/news/patterson-companies-completes-aaquisition-by-patient-square-capital/
17. Benzinga, "What Does Dental Player Patterson's $4.1 Billion Deal Mean For Other Players?" 2024. https://www.benzinga.com/24/12/42470172/
18. MedTech Dive / FierceBiotech, "ZimVie to sell to investment firm ArchiMed for about $730M," 2025. https://www.medtechdive.com/news/zimvie--sell-archimed-730m/753691/
19. A-dec, Integrity Code: Business Conduct and Ethics (company description). https://dental.a-dec.com/-/media/adecdotcom/resource-center/not-indexed/company-information/a-dec-integrity-code-business-conduct-and-ethics.pdf
20. Planmeca, Company Profile. https://www.planmeca.com/de/company/
21. GC America, Company Profile. https://www.gc.dental/america/company
22. Business Research Insights / Mordor Intelligence, "Dental Equipment and Consumables Market" (consumables share, scanner pricing, digital growth), 2026. https://www.businessresearchinsights.com/market-reports/dental-equipment-and-consumables-market-108464
23. The Insight Partners (via GlobeNewswire), "Dental Implant Market to Reach US$14.42 Billion by 2034" (US$6.93B in 2025; 8.5% CAGR), 2026. https://www.globenewswire.com/news-release/2026/07/09/3324575/0/en/
24. Fortune Business Insights / Grand View Research, "Clear Aligners Market" (size, ~15% CAGR, adult share), 2026. https://www.fortunebusinessinsights.com/industry-reports/clear-aligners-market-101377; https://www.grandviewresearch.com/industry-analysis/clear-aligners-market
25. CDC, 2024 Oral Health Surveillance Report — Selected Findings. https://www.cdc.gov/oral-health/php/2024-oral-health-surveillance-report/selected-findings.html
26. Population Reference Bureau, "Fact Sheet: Aging in the United States" (58M in 2022 to 82M by 2050). https://www.prb.org/resources/fact-sheet-aging-in-the-united-states/
27. ADA Health Policy Institute, "Practice Ownership Trends in Dentistry — A New Look," June 2025 (DSO affiliation rates). https://www.ada.org/-/media/project/ada-organization/ada/ada-org/files/resources/research/practice_ownership_trends_dentistry_new_look_.pdf
28. In Practise, "Align Technology: Growth of the DSO Channel," and Becker's Dental Review on DSO/PE consolidation, 2024–2025. https://inpractise.com/articles/align-technology-growth-of-the-dso-channel
29. HRSA, Designated Health Professional Shortage Areas Statistics — Dental Health, March 31, 2026. https://data.hrsa.gov/Default/GenerateHPSAQuarterlyReport/?source=soc-web-STAFF
30. ADA Health Policy Institute, "Dental Hygienist Shortage," April 2026. https://www.ada.org/resources/research/health-policy-institute/dentist-workforce/dental-hygienist-shortage
31. Electronic Code of Federal Regulations, "21 CFR Part 872 — Dental Devices"; U.S. FDA, "Classify Your Medical Device," 2025. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-872; https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device
32. U.S. FDA, "Class I and Class II Device Exemptions." https://www.fda.gov/medical-devices/classify-your-medical-device/class-i-and-class-ii-device-exemptions
33. U.S. FDA, "Quality Management System Regulation (QMSR)," effective February 2, 2026. https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
34. McOmie Dentistry, "Invisalign Patents Are Running Out — What Does This Mean For Clear Aligners?" (foundational patents expired ~2017). https://mcomiedentistry.com/invisalign-patents-running-out-people-wanting-invisalign-braces/
35. Macrotrends, "Dentsply Sirona (XRAY) — Dividend and Market Cap History," 2026. https://www.macrotrends.net/stocks/charts/XRAY/dentsply-sirona/dividend-yield-history